The SIL (SCL interrupting locus) gene was initially discovered at the site of a genomic rearrangement in a T-cell acute lymphoblastic leukemia cell line. This rearrangement, which occurs in a remarkably site-specific fashion, is present in the leukemic cells of 16 to 26% of patients with T-cell acute lymphoblastic leukemia. We have now cloned a normal SIL cDNA from a cell line which does not carry the rearrangement. The SIL cDNA has a long open reading frame of 1,287 amino acids, with a predicted molecular size of 143 kDa. The predicted protein is not homologous with any previously described protein; however, a potential eukaryotic topoisomerase I active site was identified. Cross-species hybridization using a SIL cDNA probe indicated that the SIL gene was conserved in mammals. A survey of human and murine cell lines and tissues demonstrated SIL mRNA to be ubiquitously expressed, at low levels, in hematopoietic cell lines and tissues. With the exception of 11.5-day-old mouse embryos, SIL mRNA was not detected in nonhematopoietic tissues. The genomic structure of SIL was also analyzed. The gene consists of 18 exons distributed over 70 kb, with the 5' portion of the gene demonstrating alternate exon utilization.
The SIL (SCL interrupting locus) gene was initially discovered at the site of a genomic rearrangement in a T-cell acute lymphoblastic leukemia cell line. This rearrangement, which occurs in a remarkably site-specific fashion, is present in the leukemic cells of 16 to 26% of patients with T-cell acute lymphoblastic leukemia. We have now cloned a normal SIL cDNA from a cell line which does not carry the rearrangement. The SIL cDNA has a long open reading frame of 1,287 amino acids, with a predicted molecular size of 143 kDa. The predicted protein is not homologous with any previously described protein; however, a potential eukaryotic topoisomerase I active site was identified. Cross-species hybridization using a SIL cDNA probe indicated that the SIL gene was conserved in mammals. A survey of human and murine cell lines and tissues demonstrated SIL mRNA to be ubiquitously expressed, at low levels, in hematopoietic cell lines and tissues. With the exception of 11.5-day-old mouse embryos, SIL mRNA was not detected in nonhematopoietic tissues. The genomic structure of SIL was also analyzed. The gene consists of 18 exons distributed over 70 kb, with the 5' portion of the gene demonstrating alternate exon utilization.
Nonrandom chromosomal translocations or deletions present in specific malignancies have been recognized for the past 30 years, since the association of the Ph chromosome with chronic myelogenous leukemia (20) . The analysis of these recurring chromosomal abnormalities at a molecular level has identified numerous proto-oncogenes and growthaffecting genes (for a review, see reference 23). These rearrangements often occur at the sites of transcriptionally active DNA, which may be in a more open chromatin configuration and thus more susceptible to chromosomal breakage and rejoining (17). Chromosomal breakpoints often involve genes that are important for the growth or development of the cell that undergoes the translocation; the classic example is seen in Burkitt's lymphoma, in which the c-myc and immunoglobulin genes are disrupted and brought into chromosomal contiguity (18) .
Traditionally, these chromosomal abnormalities have been identified cytogenetically on preparations of metaphase chromosomes. Recently, while investigating the genomic structure of the newly described SCL (TCL5, tal-J) gene (6, 7, 9, 13) , a member of the basic helix-loop-helix family of transcription factors, we identified a frequent, site-specific chromosomal deletion that involved SCL and a previously unidentified locus that we called SIL (for SCL interrupting locus) (4) . This interstitial deletion is the first known instance whereby two genes, neither one of which is an antigen receptor gene, are joined through the action of the V(D)J recombinase system. The deletion occurs below the level of conventional cytogenetic detection and leads to a fusion mRNA between SIL and SCL. A 5.5-kb SIL transcript, distinct from SCL, was identified in normal tissues by Northern (RNA) blot hybridization (4) . To better understand how disruption of the SIL gene may be relevant to the development of these T-cell leukemias and what its normal function might be, we proceeded to clone the SIL cDNA, determine its genomic structure, and examine its spectrum of expression. * Corresponding author.
MATERIALS AND METHODS
DNA and RNA isolation and analysis. DNA and RNA were isolated from cell lines and tissues by the guanidinium isothiocyanate method (11) . DNA samples (10 ,ug) were digested to completion with restriction endonucleases as recommended by the supplier (Bethesda Research Laboratories), size fractionated on 0.8% agarose gels, and transferred to nitrocellulose membranes by the Southern method (25) . RNA samples [10 jig of total RNA or 2 jig of poly(A) RNA] were size fractionated on a 1.0% agarose-formaldehyde gel and transferred to nitrocellulose membranes (11) . Hybridizations were performed with nick-translated 32p_ labeled probes and washed under standard conditions (6) , with the highest-stringency washes consisting of 0.1% sodium dodecyl sulfate and 0.1x SSC (SSC is 0.15 M NaCl plus 0.015 M sodium citrate) at 52°C. Low-stringency hybridizations, using a human probe on nonhuman Southern and Northern blots, were performed in a similar fashion, with the highest stringency wash at 42 instead of 52°C. mRNA half-life was determined by incubating K562 cells in the presence of actinomycin D (50 ,ug/ml; Sigma Chemical Co.) and harvesting the cells at 0.5, 1.0, 2.0, 4.0, and 8.0 h. RNA was extracted, and 10 jig from each time point was run on a 1.0% agarose-formaldehyde gel, transferred to a nitrocellulose membrane, and hybridized to a SIL probe. mRNA half-life was determined by measuring the decline in SIL signal on the autoradiograph.
Genomic and cDNA cloning. cDNA phage clones were obtained from a human bone marrow cDNA library and a cDNA library constructed from the SUPT1 T-cell lymphoma cell line (15) . Both libraries were constructed in lambda ZAP II (Stratagene) as previously described (3) . Genomic phage clones were obtained by screening a human placental genomic library constructed in lambda FIX II (Stratagene). Relevant cDNA and genomic restriction fragments were subcloned into the pGem7zf (Promega) and pBluescript (Stratagene) plasmid vectors.
Sequence analysis. Plasmid inserts were sequenced on both strands of DNA by the dideoxy-chain termination method, using Sequenase polymerase (U.S. Biochemical) and proto-cols. Both nested deletion mutants (Erase-A-Base system; Promega) and synthetic oligonucleotide primers were used. An IBM PS/2 with PC-Gene (Intelligenetics) was used for sequence analysis and manipulation. Genomic and cDNA sequences were compared with those in the GenBank data base. Protein sequences were compared with those in the SWISSPROT data base.
RNase protection assay. Relevant genomic or cDNA restriction fragments were subcloned into plasmids, and uniformly 32p labeled antisense RNA was synthesized by using T7, T3, or SP6 RNA polymerase and Gemini riboprobe reagents (Promega). The radiolabeled antisense RNA (2 x 105 cpm) was hybridized to 30 jig of sample RNA for 12 to 16 h at 50°C. The samples were then subjected to RNase digestion and size fractionated on a 6% acrylamide-7 M urea denaturing gel (22) .
Oligonucleotide synthesis. Oligonucleotides for sequencing and polymerase chain reaction (PCR) amplification were synthesized with an Applied Biosystems DNA synthesizer (model 380B) and used without further purification.
RACE PCR cloning of the SIL 5' end. A modification of the RACE (rapid amplification of cDNA ends) technique (14) was used to clone the 5' end of SIL. Total cellular RNA (10 ,ug) from the T-cell line Jurkat (16) or HSB-2 (1) was annealed to 10 ng of a SIL exon 5 antisense oligonucleotide, 5'-AGTCGGATGGTCTTCTCAGT-3', by heating the mixture to 65°C for 5 min and then chilling it on ice. Moloney murine leukemia virus reverse transcriptase (200 U; Bethesda Research Laboratories) was used for first-strand cDNA synthesis, according to the supplier's recommended protocol, at 45°C for 1 h. First-strand cDNA was separated from the reaction by using a Sephacryl 300 spun column (Pharmacia) as recommended by the manufacturer. An oligo(dA) tail was added to the 3' end of the cDNA by incubating 15 pl of the recovered first-strand cDNA with 0.5 ,ul of 10 mM dATP, 4 RI of 5 x tailing buffer, and 15 U of terminal deoxynucleotidyltransferase for 5 min at 37°C and 5 min at 65°C. The tailed first-strand cDNA was then diluted to 200 p1, and 1 to 3 pl was used for PCR amplification. Amplification was performed by using a SIL exon 4 antisense oligonucleotide, 5'-CTGTAGTAACTGAGATGTA-3', and a universal 5' oligonucleotide, 5'-GACTCGAGTCG ACATCGAT17-3', containing Sall, Clal, and XhoI restriction sites. Thermal cycling was carried out for 35 cycles of 95°C for 45 s, 48°C for 45 s, and 72°C for 2 min. The PCR products were then extracted with phenol-chloroform, digested with KpnI and ClaI, and ligated into pBluescript II.
Nucleotide sequence accession number. The nucleotide sequence of the composite SIL cDNA (see Fig. 2 ) has been deposited in GenBank under accession number M74558.
RESULTS

SIL cDNA cloning. Previous experiments demonstrated
that the normal SIL transcript unit was 5.5 kb (4). One million recombinant phage clones from a human bone marrow cDNA library were screened with a probe containing a portion of the SIL transcript unit as previously described (4) . A single hybridizing clone (clone 31.4; Fig. 1 ) was purified, subcloned, and sequenced. RNase protection assays using the insert from clone 31.4 as a probe did not protect the 5' portion of the clone in any test RNA (data not shown), suggesting that the 5' portion of this single clone most likely was a cloning artifact. A nonreiterated fragment (1.1KR; clones from an unamplified SUPT1 (a T-cell lymphoma cell line [15] ) cDNA library. Three hybridizing clones were purified and subcloned. All had inserts of approximately 5 kb, and sequence analysis along with extensive restriction mapping indicated that the three clones were all quite similar. The 5' ends of all three clones lay within 12 nucleotides of one another, while the 3' ends were all within 26 nucleotides of one another. The longest clone (7S; Fig. 1 ) was sequenced on both strands of DNA in its entirety; selected portions of the other two clones were sequenced. RNase protection transcript mapping experiments (described below) indicated that none of the cDNA clones were full length; therefore, the RACE technique (14) was used to generate clones, such as clone 96 ( Fig. 1) , extending further 5'. The sequence and predicted protein(s) of a composite SIL cDNA are presented in Fig. 2 ; alternate splicing events are described in the figure legend. An ATG triplet in good context for protein initiation (ATCATGG) is seen at nucleotide 366; this ATG is preceded by stop codons in all three reading frames. There is a long open reading frame of 3,861 nucleotides, potentially encoding a protein of 1,287 amino acids, with a predicted molecular size of 143 kDa.
RNase protection analysis and the RACE cloning strategy (14) were used to determine the SIL transcript initiation site. A total of 18 independent RACE clones from HSB-2 and Jurkat mRNAs were sequenced. The majority of these clones ended within 1 nucleotide of nucleotide 1 in Fig. 2 , four additional clones ended at a second cluster 28 nucleotides upstream, and the remainder were scattered within 55 nucleotides of nucleotide 1. To confirm that nucleotide 1 represented the major transcript initiation site, a 0.4-kb genomic fragment encompassing exon 1 was isolated and sequenced ( Fig. 3A ). When this genomic fragment was used as an RNase protection probe, a 112-bp fragment was protected ( Fig. 3B ) in all mRNA samples tested. This 112-bp protected fragment corresponds precisely to nucleotide 1 as defined by the RACE clones. The sequence surrounding this nucleotide, CTCAGTTCC, is in good agreement with the consensus transcription start sequence of PyPyC(A/G)PyPy PyPy (10) . A very similar sequence, TTCAGTTT-C, is found 28 nucleotides upstream, where four additional clones ended. Several CCAAT boxes and a potential Spl binding site are indicated in Fig. 3B .
None of the SIL cDNA clones contained a poly(A) tail. However, since the clones were obtained from an oligo(dT)- Composite nucleotide sequence and predicted protein of the SIL cDNA. Nucleotide 1 represents the 5' extent of the SIL cDNA, as defined by RACE cloning and RNase protection (see text). The initiation ATG codon, at nucleotide 366, is preceded by stop codons (underlined) in all three reading frames. Splice junctions are indicated by brackets. Exon 2 (nucleotides 113 to 322) is spliced out of some mRNA species. The boxed region of exon 7 (nucleotides 862 to 1002) is spliced out of a minority of mRNA species (see text) and is bounded by GT splice donor and AG splice acceptor sequences. A single cDNA clone extended exon 5 133 nucleotides beyond the usual splice donor site into the contiguous intron and subsequently spliced at the normal exon 6 splice acceptor site. This exon, containing all of exon 5 and a portion of the adjacent intron, is referred to as exon Sa. The protein predicted by this cDNA clone is referred to as SIL form C (see text). primed cDNA library, and three independent clones began within 26 nucleotides of one another, it seemed likely that these clones were near the 3' end. When a genomic clone encompassing exon 18 (the terminal SIL exon; see below) was sequenced and compared with the longest SIL cDNA clone, an AATAAA polyadenylation signal was noted 11 nucleotides 3' of the end of the cDNA clone. These data indicate that the 3' end of a full-length SIL cDNA clone is, in all likelihood, 20 to 30 nucleotides 3' of this polyadenylation signal.
SIL mRNA expression. Northern blot analysis of mRNA extracted from a variety of human cell lines and tissues indicated that the 5.5-kb SIL transcript was expressed ubiquitously, at low levels, in all hematopoietic cell lines and hematopoietic tissues studied ( Table 1 ). The half-life of the SIL message, based on actinomycin D inhibition experiments, was 2 h in the K562 cell line. SIL message was not detected in any other human tissue studied. To extend this spectrum of expression, a variety of murine tissues were studied by Northern blotting. A human SIL cDNA probe (1.1KR; Fig. 1 ) identified a single 5.5-kb transcript in several murine cell lines, including uninduced murine erythroleukemia, F9 teratocarcinoma, and D3 embryonic stem cells. Table 1 demonstrates that the only murine tissues (of those studied) expressing SIL mRNA were thymus and 11.5-day whole mouse embryos. SIL genomic structure. To determine the exon/intron structure of the SIL gene, a human placental genomic library was screened with several SIL cDNA probes. The overlapping genomic phage clones were compared with the SIL cDNA, and the exon/intron structure is shown in Fig. 4 . The exon/intron borders were sequenced; all splice acceptor sequences contained the AG dinucleotide sequence. However, a single splice donor had a GC dinucleotide instead of the usual GT splice donor sequence. The nucleotide sequence surrounding this splice donor is AAGgcaagt, which is in very good agreement with the consensus sequence of (C/A)AGgt(aIg)agt except for the C-for-T replacement. Two splice donor sequences that violate the GT rule have been reported before (21) , the variant dinucleotide being GC in both instances.
Examination of the genomic structure of both SIL and SCL (3) indicates that the previously reported SILISCL rearrangement (4) juxtaposes SIL intron 1 with SCL intron 1. This leads to formation of a fusion SILISCL mRNA, with SIL exon 1 splicing to SCL exon 3, in a head-to-tail fashion Fig. 5 . SCL exon lb is a transcript initiation exon (3) and lacks a splice acceptor site. Although SIL exon 1 could potentially splice to SCL exon 2b, we did not detect this mRNA form. This splicing pattern is similar to that seen with the normal SCL mRNA (3), in which exon 2b is incorporated into only a minority of mature SCL mRNA forms. As both SIL exon 1 and SCL exon 3 are 5' untranslated exons, the SILISCL fusion mRNA predicts a full-length SCL protein.
The predicted SIL protein. Three related but distinct forms of the SIL protein are encoded by the SIL cDNA clones. RNase protection analysis (data not shown) was used to determine the relative abundance of these different forms in human bone marrow and a variety of hematopoietic cell lines, including Jurkat, SUPT11, HSB-2, and K562. Form A (Fig. 6A ) was the most prevalent mRNA species in all cell lines studied and encodes a protein of 1,287 amino acids, residues 1 to 1287 in Fig. 2 . Form B differed from form A by an in-frame internal deletion of 141 nucleotides (Fig. 2) and was less abundant but easily detectable by RNase protection. Form B predicts a protein of 1,240 amino acids, residues 1 to 165 and 213 to 1287, with residues 166 to 212 being deleted. Form C, which predicts an amino-terminal truncated SIL protein of 1,150 amino acids (residues 138 to 1287), was undetectable by RNase protection, indicating that it represented a low-abundance transcript in the cell lines and tissues examined. All three forms of the predicted SIL protein were identical for amino acid residues 213 to 1287. None of the three forms showed significant homology with any of the protein sequences deposited in the SWISSPROT data base. The predicted SIL protein is rich in serine, proline, and asparagine residues, has a predicted isoelectric point of 5.92, and has no membrane-spanning domains. A potential eukaryotic topoisomerase I active site was identified by using the PROSITE function (5) of PC-Gene. The consensus sequence for eukaryotic topoisomerase I proteins, Ex(8)SKx(2)Y(L/I/M), with the tyrosine residue being the active site (12, 19) , is indicated in Fig. 6B . All of the protein sequences deposited in the SWISSPROT data base containing this consensus sequence are known eukaryotic topoisomerase I proteins (5) .
DISCUSSION
In many instances of recurrent, nonrandom chromosomal translocations associated with specific malignancies, the translocations disrupt genes that are essential for the growth or differentiation of the involved cell. The SIL gene, which is frequently disrupted in the leukemic cells from patients with 12 3  4  567  8 9 10  111213  14 15  16 17  18   11  11I II  I I I  I I  I I T-cell acute lymphoblastic leukemia (ALL), has now been cloned and sequenced. On the basis of the cDNA sequence, three distinct but similar forms of the SIL protein are predicted. One form (form A) predominates in all tissues and cell lines studied, and sequence analysis predicts a protein of 143 kDa. The predicted SIL protein has a potential eukaryotic topoisomerase I active site. On the basis of protein sequence similarities to known topoisomerases, a recent review (26) has speculated that two proteins known to be involved in intrachromosomal DNA recombination, mammalian RAGI (recombinase-activating gene I) (24) and the yeast HPR1 gene product (2), may have topoisomerase I activity. Similar to the topoisomerases and these two proteins, it is possible that the SIL gene product functions in either DNA recombination or replication. There is no other similarity yet seen among SIL and these other proteins.
The genomic structure of SIL demonstrates a fairly large gene, consisting of 18 exons distributed over 70 kb. Transcripts that differ at their 5' ends are generated by alternate mRNA splicing in both the 5' untranslated region and the predicted coding region. This type of alternate splicing had been reported for other genes (reference 3 and references therein) and may be relevant to the function of the SIL gene product(s). As shown in Fig. 5 , the SILISCL rearrangement leads to deletion of the body of the SIL gene on the rearranged allele. A limited survey of cell lines and tissues indicated that SIL mRNA expression could be detected only in hematopoietic or embryonic cell lines and tissues. Both Northern and RNase protection analysis indicated that SIL was expressed at low levels in all hematopoietic tissues and cell lines studied. However, with the exception of whole mouse embryos and embryonic cell lines, we did not detect SIL transcripts in any nonhematopoietic tissues. This limited spectrum of expression suggests that the SIL gene product may play a role exclusively in hematopoietic growth or differentiation. Alternatively, SIL may be expressed in nonhematopoietic tissues, at levels too low to be detected by Northern or RNase protection analysis. Preliminary experiments (3a) indicate that SIL mRNA expression decreases to undetectable levels when certain cell lines (HL60 and U937) are treated with agents that induce terminal differentiation, suggesting that the SIL gene product is active when cells are in the proliferative but not the terminally differentiated state.
It remains unclear how the SILISCL rearrangement, seen in the leukemic cells from 16 to 26% of T-cell ALL patients (4a, 8) , may contribute to leukemogenesis. T-cell ALL patients with a t(1;14) translocation involving SCL all show either a functional or structural disruption of the normal SCL 5' regulatory region, leading to inappropriate SCL mRNA expression (reference 3 and references therein). We have previously speculated that inappropriate expression of SCL SCL 14 15 16 17 in these patients may contribute to malignant transformation, in a manner analogous to inappropriately expressed c-myc associated with Burkitt's lymphoma (18) . It is possible that the SILISCL deletion contributes to malignant transformation in a manner similar to that hypothesized for patients with t(1;14) translocations, as the SILISCL rearrangement also disrupts the 5' regulatory region of SCL. The SILISCL rearrangement produces a fusion mRNA (4) potentially encoding a full-length SCL protein. Furthermore, this SILI SCL fusion mRNA is not an artifact of tissue culture. We have recently studied mRNA from the leukemic blasts of several patients with newly diagnosed T-cell ALL, and all express an identical SILISCL fusion message (4a) . The net effect of this rearrangement is to put SCL transcription under control of the SIL 5' regulatory region. In this light, it is important to note that while SCL is not normally expressed in T cells (7) , SIL is. Therefore, in T cells that have undergone a SILISCL deletion, the 5' regulatory region of SCL, a gene not normally expressed in T cells, is replaced by the 5' regulatory region of SIL, which normally is expressed in T cells, leading to inappropriate SCL expression. While it is possible that SIL functions as a tumor suppressor gene and that the deletion of one copy of SIL contributes to malignant transformation, we have no reason to believe that this is the case. In sum, we have taken advantage of a commonly occurring chromosomal deletion, associated specifically with T-cell ALL, to identify and characterize the cDNA and genomic structure of two distinct genes, SCL (3) and SIL (this report). It seems very likely that the fusion of these two genes contributes significantly to the malignant transformation of T cells. 
